Sugi Predict

Sugi Predict / Compounds / SCHEMBL355647

SCHEMBL355647

SCHEMBL355647

CC(C)(C)OC(=O)c1ccc(N)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 4/20 0.56
▸ CHRM2 P08172 1/20 0.52
▸ CHRM3 P20309 1/20 0.52
▸ MAOA P21397 1/20 0.52
▸ HTR2C P28335 1/20 0.52
▸ CHRNA4 P43681 1/20 0.52
▸ HTR3A P46098 1/20 0.52
▸ KCNH2 Q12809 1/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.52
▸ GAA P10253 1/20 0.44
▸ JAK2 O60674 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CYP3A4 P08684 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ NR1H2 P55055 1/20 0.40
▸ TSHR P16473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29590117 0.87 NR1H4 (0.43) NR1H4CHRM2CHRM3MAOAHTR2C
SCHEMBL24269548 0.87 NR1H4 (0.43) NR1H4CHRM2CHRM3MAOAHTR2C
SCHEMBL3843873 0.83 NR1H4 (0.54) NR1H4GAAALDH1A1TSHRHPGD
SCHEMBL1186570 0.81 GAA (0.67) NR1H4GAACA1CA2CA12
SCHEMBL3288448 0.81 ADRB2 (0.52) NR1H4MAOAGAACA1CA2
SCHEMBL10494053 0.81 STAT3 (0.45) NR1H4CA1CA2CA12CA9
SCHEMBL18267318 0.81 RAB9A (0.52) CYP3A4ALDH1A1HPGDALOX15NPC1
SCHEMBL145288 0.81 GAA (0.66) NR1H4CHRM2CHRM3MAOAHTR2C
SCHEMBL17185583 0.80 GABRG2 (0.43) NR1H4CA1CA2CA12CA9
SCHEMBL436207 0.80 ALDH1A1 (0.51) NR1H4GAACYP3A4ALDH1A1NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
EP-4725944-A1 NEW METHOD FOR PREPARING OXOPYRIDINE COMPOUND, AND KEY INTERMEDIATE AND USE Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) 2026-04-15 — — EP disclosed
US-12595255-B2 Heteroaryl-substituted imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2026-04-07 — — US disclosed
US-12421211-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2025-09-23 — — US disclosed
CN-115066417-B Factor XIa inhibitors 上海京新生物医药有限公司 2025-05-02 — — CN disclosed
WO-2024251276-A1 NEW METHOD FOR PREPARING OXOPYRIDINE COMPOUND, AND KEY INTERMEDIATE AND USE 成都施贝康生物医药科技有限公司 2024-12-12 — — WO disclosed
US-20240368117-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-11-07 — — US disclosed
EP-4211116-B1 NOVEL HETEROCYCLIC ANTIBIOTICS HOFFMANN LA ROCHE (CH) 2024-08-07 — — EP disclosed
CN-118119609-A Imidazole derivatives and their use as antibiotics 豪夫迈·罗氏有限公司 2024-05-31 — — CN disclosed
EP-4370514-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS F. Hoffmann-La Roche AG (CH) 2024-05-22 — — EP disclosed
EP-1996563-A1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2008-12-03 — — EP disclosed
CN-100343238-C Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2007-10-17 — — CN disclosed
WO-2007093507-A1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 — — WO disclosed
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-16 — — US disclosed
US-20070082921-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB 2007-04-12 — — US disclosed
US-20050043336-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-02-24 — — US disclosed
CN-1585754-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-02-23 — — CN disclosed
EP-1444210-A1 QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2004-08-11 — — EP disclosed
WO-2003040108-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 — — WO disclosed
US-4234600-A Combating arthropods with N-benzoyl-N'-tert.-alkoxycarbonylphenyl-(thio) ureas BAYER AKTIENGESELLSCHAFT (DE) 1980-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421211-B2 Heterocyclic compounds F12, C1R, MRPL21 NR1H4 433/4885CHRM2 1403/4885CHRM3 2129/4885
US-20050043336-A1 Quinazoline derivatives as antitumor agents ERBB2, ERBB3, ABL1 NR1H4 3193/4885CHRM2 547/4885CHRM3 956/4885
US-20070082921-A1 Quinazoline derivatives as antitumor agents ERBB2, EGFR, ERBB4 NR1H4 2587/4885CHRM2 1761/4885CHRM3 1890/4885
US-20240368117-A1 HETEROCYCLIC COMPOUNDS F12, C1R, MRPL21 NR1H4 433/4885CHRM2 1403/4885CHRM3 2129/4885
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 NR1H4 520/4885CHRM2 2240/4885CHRM3 4231/4885
US-12595255-B2 Heteroaryl-substituted imidazole derivatives CLIC1, CYP2B6, CYP2D6 NR1H4 370/4885CHRM2 1034/4885CHRM3 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.